NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,598 | +699.4% | 160,886 | +2880.5% | 0.03% | +650.0% |
| Q1 2023 | $325 | -47.3% | 5,398 | -35.9% | 0.00% | -50.0% |
| Q4 2022 | $617 | -100.0% | 8,415 | -66.7% | 0.01% | -66.7% |
| Q3 2022 | $1,917,000 | +702.1% | 25,236 | +633.8% | 0.02% | +700.0% |
| Q2 2022 | $239,000 | -81.6% | 3,439 | -78.1% | 0.00% | -70.0% |
| Q1 2022 | $1,300,000 | +31.3% | 15,696 | +19.0% | 0.01% | +100.0% |
| Q4 2021 | $990,000 | +54.7% | 13,189 | +139.6% | 0.01% | +66.7% |
| Q3 2021 | $640,000 | -72.7% | 5,505 | -48.0% | 0.00% | -72.7% |
| Q2 2021 | $2,346,000 | +67.6% | 10,577 | -0.1% | 0.01% | +57.1% |
| Q1 2021 | $1,400,000 | -5.5% | 10,591 | +23.8% | 0.01% | -12.5% |
| Q4 2020 | $1,481,000 | +509.5% | 8,558 | +108.7% | 0.01% | +300.0% |
| Q2 2020 | $243,000 | -81.3% | 4,100 | -78.8% | 0.00% | -83.3% |
| Q1 2020 | $1,301,000 | +134.0% | 19,317 | +192.9% | 0.01% | +140.0% |
| Q4 2019 | $556,000 | +103.7% | 6,596 | +80.5% | 0.01% | +150.0% |
| Q3 2019 | $273,000 | -54.4% | 3,654 | -61.4% | 0.00% | -50.0% |
| Q2 2019 | $599,000 | -79.5% | 9,471 | -84.4% | 0.00% | -85.2% |
| Q1 2019 | $2,917,000 | -20.8% | 60,565 | -45.0% | 0.03% | -15.6% |
| Q4 2018 | $3,685,000 | +122.9% | 110,053 | +249.0% | 0.03% | +166.7% |
| Q3 2018 | $1,653,000 | -22.9% | 31,537 | -53.9% | 0.01% | -36.8% |
| Q2 2018 | $2,143,000 | +1561.2% | 68,455 | +1058.5% | 0.02% | +1800.0% |
| Q1 2018 | $129,000 | +7.5% | 5,909 | -0.8% | 0.00% | 0.0% |
| Q4 2017 | $120,000 | -69.1% | 5,955 | -69.5% | 0.00% | -66.7% |
| Q3 2017 | $388,000 | +109.7% | 19,545 | +82.9% | 0.00% | +50.0% |
| Q2 2017 | $185,000 | +105.6% | 10,686 | -3.6% | 0.00% | +100.0% |
| Q1 2017 | $90,000 | -63.6% | 11,086 | -64.8% | 0.00% | -50.0% |
| Q4 2016 | $247,000 | +120.5% | 31,482 | +139.9% | 0.00% | +100.0% |
| Q3 2016 | $112,000 | – | 13,123 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |